Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 version 1.0 viral load test

J Acquir Immune Defic Syndr. 2010 Aug;54(4):442-4. doi: 10.1097/QAI.0b013e3181d01d1d.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome / blood*
  • Acquired Immunodeficiency Syndrome / drug therapy
  • Acquired Immunodeficiency Syndrome / economics*
  • Anti-HIV Agents / therapeutic use
  • Anti-Retroviral Agents / economics
  • Anti-Retroviral Agents / therapeutic use
  • Cost of Illness*
  • HIV-1 / genetics*
  • Humans
  • RNA, Viral / blood*
  • Viral Load / methods*
  • Viremia / blood
  • Viremia / diagnosis
  • Viremia / drug therapy

Substances

  • Anti-HIV Agents
  • Anti-Retroviral Agents
  • RNA, Viral